| 1. |
- Bronge, L, et al.
(författare)
-
White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype
- 1999
-
Ingår i: Dementia and geriatric cognitive disorders. - : S. Karger AG. - 1420-8008 .- 1421-9824. ; 10:2, s. 89-96
-
Tidskriftsartikel (refereegranskat)abstract
- To analyse the influence of apolipoprotein E (APOE) genotype on the extent of white matter lesions (WMLs) in Alzheimer’s disease (AD), we examined 60 AD patients with magnetic resonance imaging. The WMLs were rated visually in different brain regions. The patients with the APOE genotype σ4/4 had more extensive WMLs in the deep white matter than patients with genotypes σ3/3 and σ3/4. There was a correlation with age for WMLs in the deep white matter in patients with the APOE σ3/3 genotype. In patients carrying at least one σ4 allele, the WMLs showed no age correlation. The results could imply that in APOE allele σ4 carriers, the WMLs represent a pathological process related to the aetiology of the disease.
|
|
| 2. |
- Blomberg, M, et al.
(författare)
-
Cerebrospinal fluid tau levels increase with age in healthy individuals
- 2001
-
Ingår i: Dementia and geriatric cognitive disorders. - : S. Karger AG. - 1420-8008 .- 1421-9824. ; 12:2, s. 127-132
-
Tidskriftsartikel (refereegranskat)abstract
- Cerebrospinal fluid (CSF) tau is a promising biochemical ante-mortem marker for Alzheimer’s disease (AD). Levels are increased in AD compared to other dementias, neurological diseases and healthy controls. An age-related decrease in both soluble tau and tau bound to paired helical filaments has been shown in brains from non-demented subjects. To study tau levels in normal ageing, we investigated CSF in 29 healthy individuals aged 45–80 years. A statistically significant increase in CSF tau with increasing age was found which might be caused by neuronal loss during normal ageing and redistribution of soluble tau from the brain into CSF. We could not demonstrate any influence by the APOE genotype, though larger populations have to be investigated to confirm this result. In conclusion, we found an age-dependent increase in CSF tau in healthy individuals. We emphasise the importance of establishing an age-dependent interval of CSF tau in non-demented subjects.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Ingelson, M, et al.
(författare)
-
Tau immunoreactivity detected in human plasma, but no obvious increase in dementia
- 1999
-
Ingår i: Dementia and geriatric cognitive disorders. - : S. Karger AG. - 1420-8008 .- 1421-9824. ; 10:6, s. 442-445
-
Tidskriftsartikel (refereegranskat)abstract
- <i>Tau</i> proteins are central to the neuropathology of Alzheimer’s disease and <i>tau</i> levels in cerebrospinal fluid are elevated in affected individuals. In this study, we investigated the presence of <i>tau</i> in plasma from subjects with Alzheimer’s disease (n = 16), frontotemporal dementia (n = 10), vascular dementia (n = 16) and from healthy controls (n = 15). By using an ELISA with monoclonal <i>tau</i> antibodies, <i>tau</i> immunoreactivity was detected in approximately 20% of the subjects. However, no difference between the disease and control groups was seen. After gel filtration of <i>tau</i> immunopositive plasma, the peak reactivity was found in the 160-kD fraction, indicating the source to be <i>tau</i>-like molecules of high-molecular-weight or polymers of low-molecular-weight <i>tau</i> isoforms. We conclude that measurements of <i>tau</i> in plasma cannot be utilized diagnostically for Alzheimer’s disease or for the other dementias investigated.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
